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AbsTrACT
Objective Neurofilament is a biomarker of axonal 
injury proposed as a useful adjunct in the monitoring 
of patients with multiple sclerosis (MS). we conducted 
a systematic review and meta-analysis of case–control 
studies that have measured neurofilament light chain 
(NfL) levels in cerebrospinal fluid (CSF) of people with 
MS (pwMS), in order to determine whether, and to what 
degree, CSF NfL levels differentiate MS from controls, or 
the subtypes or stages of MS from each other.
Methods Guidelines on Preferred Reporting items for 
Systematic Reviews and Meta-Analyses were followed. 
electronic databases were searched for published 
and ’grey’ literature, with 151 hits. Of 51 full articles 
screened, 20 were included in qualitative analysis, and 
14 in meta-analysis.
results CSF NfL was higher in 746 pwMS than 435 
(healthy and disease) controls, with a moderate effect 
size of 0.61 (p < 0.00001). Mean CSF NfL levels were 
significantly higher in 176 pwMS with relapsing disease 
than 92 with progressive disease (2124.8 ng/L, SD 3348.9 
vs 1121.4 ng/L, SD 947.7, p = 0.0108). CSF NfL in 138 
pwMS in relapse (irrespective of MS subtype) was double 
that seen in 268 pwMS in remission (3080.6 ng/L, SD 
4715.9 vs 1541.7 ng/L, SD 2406.5, p < 0.0001).
Conclusions CSF NfL correlates with MS activity 
throughout the course of MS, reflecting the axonal 
damage in pwMS. Relapse is more strongly associated 
with elevated CSF NfL levels than the development of 
progression, and NfL may be most useful as a marker of 
disease ’activity’ rather than as a marker of disability or 
disease stage.
InTrOduCTIOn
Therapy for multiple sclerosis (MS) has expanded 
remarkably over the past 20 years. The updated 
2017 McDonald diagnostic criteria enable diag-
nosis and disease-modifying treatment (DMT) to 
occur earlier, and also recommend the diagnostic 
use of cerebrospinal fluid oligoclonal bands (CSF 
OCBs), which may now act as a proxy for evidence 
of dissemination in time.1 Prior to this revision the 
routine clinical use of fluid biomarkers had changed 
little since OCBs were implemented in the 1980s.
MRI remains the most commonly employed diag-
nostic and monitoring tool.2 Lesion location and 
burden are used as a prognostic aid, and once diag-
nosed, patients undergo regular imaging to assess 
white matter lesion load and monitor for adverse 
effects of DMT.3 However, standard MRI sequences 
do not fully reflect the scope of disease pathology, 
and correlation between MRI measures and clinical 
disability remains limited.4–7 It is now accepted that 
MS is not only an inflammatory disease of white 
matter but also grey matter, and that neurodegen-
eration occurs early in the disease process, and not 
merely as a consequence of demyelination.8 Patho-
logical studies demonstrate diffuse axonal damage 
throughout normal appearing white matter—find-
ings that have been replicated in vivo using MR 
spectroscopy, but the extent of diffuse white matter 
pathology does not correlate with the number of 
focal lesions on routine MRI sequences.8 9 General 
and regional MRI atrophy measures can reflect 
neurodegeneration to a degree, and correlate with 
longer-term measures of clinical disability, but are 
problematic to employ in standard practice in indi-
vidual patients.10 11 Consequently, there is a need 
for a practical biomarker to quantify and monitor 
neurodegeneration.
Neurofilament is an intermediate filament protein, 
integral for radial growth of axons during devel-
opment, and the cytoarchitecture and transport 
functions within mature neuronal axons.12 Axonal 
injury releases neurofilament into the extracellular 
space, where neurofilament light chain (NfL) can be 
measured in CSF as a biomarker of axonal degenera-
tion. Optimised assays, and now the ability to measure 
NfL levels in blood, have increased its potential for 
translation to clinical practice.13–18 However, MS is 
a heterogeneous disease, with subtypes and trajecto-
ries, in flux between relapse, remission, stability and 
progression.19 Age, gender and comorbidities can 
influence any potential biomarker, and DMTs (with 
differing mechanisms of action) are widely prescribed. 
Disparities within measures used to classify the disease 
(disability scales, clinical staging and MRI) add a 
further hurdle in standardisation. In order to account 
for predictable variability, some aspects can be stan-
dardised.20 21 Where this is not possible, large datasets 
and repeated validations are required.
To improve the power to assess the relevance and 
utility of NfL measurement, we performed a system-
atic review and meta-analysis of CSF NfL in MS.
MeThOds
Objective
The focused question was ‘To what extent do CSF 
NfL levels differentiate people with MS (pwMS) 
from (healthy or disease) controls?’ Thereafter, 
‘Can CSF NfL levels differentiate different MS 
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Figure 1 PRiSMA 2009 flow diagram. PRiSMA, Preferred Reporting items for Systematic Review and Meta-analysis.
disease stages or states’? The meta-analysis was registered with 
PROSPERO (ID CRD42017078996) and conducted according 
to a predetermined protocol.
selection criteria
Any original study quantifying NfL in CSF of pwMS was identi-
fied. No language or publication date restrictions were imposed. 
Patients of any age were included, with no restrictions on disease 
duration or subtype, time since relapse, disability, comorbidities or 
treatment.
Diagnosis had to be stated with reference to established diag-
nostic criteria. Where cohorts were not differentiated by MS 
subtype, they were named accordingly, for example ‘clinically 
definite MS (CDMS)’.22 23 Clinical and radiologically isolated 
syndromes were excluded in order to reduce the heterogeneity of 
the overall cohort. Each MS cohort required a control compar-
ator. Ideally, studies should reference guidelines on defining 
control groups, but this was not an inclusion criterion.21 Studies 
could be retrospective, cross-sectional or prospective.
CSF collection and bio-banking were required to meet criteria 
proposed by BioMS-EU.20 If these criteria were not referenced, 
the paper was required to describe CSF sampling, pre-analytical 
handling and storage techniques applied to ensure the samples 
used were of sufficient quality. Studies also had to use a vali-
dated assay, or describe the ELISA technique to satisfy inclusion. 
Assays with a coefficient of variation >25% were excluded, as 
were studies where NfL was detectable in less than 85% of either 
comparator group.
search strategy for identification of studies and methods of 
review
One author (SJM) searched electronic databases for published 
and unpublished ‘grey’ literature (online supplementary table 
1), and reviewed abstracts to assess if they met inclusion criteria 
(online supplementary table 2). Detailed review of potentially 
eligible papers followed, as per Preferred Reporting Items 
for Systematic Reviews and Meta-Analyses, 2009 guidelines 
(figure 1).24
description of studies and reasons for exclusion
In all, 68 duplicates were removed, and 100 records excluded on 
abstract alone (online supplementary table 3). Of the remaining 
51 papers, 17 studies had no control group, three measured 
NfL in a categorical way and one measured serum NfL levels. 
Seven studies were excluded on the basis that CSF NfL level 
was detectable in less than 85% of one comparator group. These 
were older studies that used a less sensitive assay.25 26 Three 
papers were excluded as NfL levels for the MS cohort had previ-
ously been published. One paper used previously published data 
from a control cohort, but compared it with a new MS cohort, 
and was included.27 In all, 20 studies met inclusion criteria.
data extraction
Data were reported as mean and SD in some papers, and as 
median and range or IQR in others. If data were not provided as 
mean and SD, the authors were contacted and asked to provide 
these values or the raw data. Authors of six studies without 
the required information did not respond to requests for data, 
leaving 14 studies for analysis.
description of studies
In total, 805 patients (638 relapsing remitting MS (RRMS), 104 
secondary progressive MS (SPMS) and 63 primary progressive 
MS (PPMS)) and 435 controls (332 non-inflammatory neurolog-
ical disease controls (NINDCs) and 103 healthy controls (HCs)) 
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Table 1 Summary table of studies included in meta-analysis
First author, year no Ms Mean age patients no controls Mean age controls
Quality (nOs)
selection (4*) Comparability (3*)
exposure 
(2*)
Piehl, 2017 39 39.6 27 35.2 ** ***
Trentini, 2014 31 49.6 15 39 *** **
Novakova, 2017a 59 37 39 (dup) 33.6 **** ***
Novakova, 2017b 43 39.7 39 33.6 **** * ***
Hakansson, 2017 22 unknown 22 32 **** ** ****
Bergman, 2016 110 37.7 113 40.2 *** **
Lam, 2015 59 45.7 44 40.4 ** **
Stilund, 2015 59 41.2 39 40.7 *** **
Villar, 2015 127 33.6 37 34.6 ** * ***
Aeinehband, 2015 48 41.2 18 30.4 *** **
Burman, 2014 63 43.8 15 40.2 ** ***
Axelsson, 2014 35 48 14 42 **** * ***
Fialová, 2013 18 38 24 33 ** **
Gunnarsson, 2011 92 37.3 28 43 *** **
Each study is scored using a star system based on three domains: (1) selection of study groups (cases and controls)—maximum 4*; (2) comparability of the groups—maximum 2*; (3) ascertainment of outcome—maximum 3*.
MS, multiple sclerosis; NOS, Newcastle-Ottawa Scale.
from 14 studies were included (online supplementary figure 1). 
The Newcastle-Ottawa Scale (NOS—a scoring system to assist 
with quality assessment of non-randomised research) was imple-
mented (table 1). However, as the NOS has not been validated 
no articles were excluded based on this score.28
Seven studies were retrospective, four prospective and 
three were cross-sectional analyses. Seven studies referenced 
BioMS-EU guidelines, and two referenced guidelines relating to 
definition of control populations.17 21 29 All 14 studies used the 
commercially available Uman NfL ELISA to measure CSF NfL, 
with a lower limit of detection of 31 ng/L documented by the 
manufacturer, and intra-assay coefficient of variation reported 
by the authors between 3.5% and ‘<15%’. Seven papers explic-
itly reported that the analysis was blinded.17 30–35
statistical analysis
Standard mean deviation and 95% CIs were calculated for each 
group in each study. If only subgroup values were available 
from the datasets provided, means were combined and the SDs 
were pooled to get the cohort mean and SD.36 Where only the 
median and range were available, mean and SD were estimated 
using Luo et al36 and Wan et al,37 respectively.36 37 If the paper 
provided data as SE of the mean, this too was converted to SD.
The individual means and SD were analysed in weighted fixed 
effect models to estimate standardised mean differences in NfL 
level between comparators (with 95% CI, and corresponding 
p value). Heterogeneity between studies was tested for, and 
documented as a Q test statistic and corresponding p value. 
Publication bias was assessed using funnel plots. Demographic 
differences between cohorts were tested for significance using 
two-way T-tests and Z-scores.
resulTs
CsF nfl in CdMs versus controls
CSF NfL levels were higher in 746 patients with CDMS (1965.8 
ng/L, SD=3102.5) than 435 controls (578.3 ng/L, SD=1212.3) 
(figure 2). MS and control groups were comparable in age (41.3 
vs 37.3 years, respectively) and sex (63% and 62% women). 
Meta-analysis revealed a statistically significant moderate effect 
size, 0.61, p<0.00001. A funnel plot (online supplementary 
figure 2) showed spread around the observed outcome, making 
publication bias unlikely.
The CSF NfL level in 332 NINDCs (643.4 ng/L, SD=1515.2) 
was double that seen in 103 HCs (368.4 ng/L, SD=224). Hetero-
geneity between study outcomes was significant in the CDMS 
versus NINDCs meta-analysis (p=0.0136), but not the CDMS 
versus HC meta-analysis. MS cohorts were demographically 
comparable (mean age 41.7 years; 56% or 65% women in the 
MS cohort compared with HC or NINDCs, respectively), with 
approximately a third of subjects in relapse. This suggests that 
differences between outcomes arise from differences between 
control populations.
CsF nfl in rrMs versus controls
CSF NfL is significantly higher in RRMS subjects (during both 
relapse and remission) than controls, p<0.00001 (figure 3). The 
effect size is larger during relapse (1.13) than remission (0.67).
In the ‘RRMS in remission’ versus controls (NINDCs) 
meta-analysis, no heterogeneity was evident, and the mean NfL 
level was five times higher in ‘RRMS in remission’ than NINDCs 
(1896.4 ng/L, SD=3371.4 versus 365.1 ng/L, SD=281.3). In 
the ‘RRMS in relapse’ versus controls meta-analysis, mean NfL 
was nine times higher in patients with RRMS (3272.2 ng/L, 
SD=5164.8 vs 364.9 ng/L, SD=275.3), but heterogeneity 
between study outcomes was significant, (p=0.0008).
As the same NINDCs were the comparator in both analyses, 
the ‘RRMS in relapse’ cohort is the source of the heteroge-
neity. Patients with RRMS ‘in relapse’ were 76% women, with a 
mean age of 35 years, whereas RRMS ‘in remission’ were 68% 
women, with a mean age of 38 years. Age and sex differences 
between the groups were not statistically significant (two-way 
T-test, p=0.104 and Z-score, p=0.37, respectively).
However, how the authors defined ‘relapse’, and thus ‘remis-
sion’, varied significantly (3online supplementary figure 3). Lam 
et al38 defined their relapse cohort as those who had relapsed 
within 4 weeks of CSF sampling. Six studies included patients 
who had relapsed within 3 months (Piehl et al,39 Villar et al,40 
Novakova et al,41 Gunnarsson et al,31 Axelsson et al30 and Aeine-
hband et al33), and Novakova et al27 used <100 days. Burman 
et al32 defined a relapse as occurring within the preceding 3 
months, or the presence of Gd +lesions on MRI, or in some 
patients a combination. The definition of disease state (relapse 
or remission) may therefore be the source of heterogeneity.
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Figure 2 Clinically definite MS versus controls (HCs and NiNDCs), subgroup and combined meta-analysis. Four studies compared CSF NfL levels in 
patients with MS with HCs, and nine studies used NiNDCs. One group (Novakova et al) used the same control cohort in two papers (Novakova a and b). 
(Novakova a) was therefore excluded from the overall analysis to avoid duplication. This study is used in later subanalyses, and a sensitivity analysis including 
it did not alter results. CSF NfL levels are higher in MS than healthy and disease controls. CDMS, clinically definite MS; CSF, cerebrospinal fluid; HCs, healthy 
controls; MS, multiple sclerosis; NfL, neurofilament light chain; NiNDCs, non-inflammatory neurological disease controls; SMD, standard mean deviation.
CsF nfl in relapse versus CsF nfl in remission
The effect of relapse on CSF NfL level was similar irrespective 
of whether patients were defined as RRMS or progressive, with 
a moderate effect size seen in each (0.51 and 0.56, p<0.0001, 
respectively) (figure 4).
Mean CSF NfL in 122 patients with RRMS in relapse (3138.9 
ng/L, SD 4980.2) was approximately twice that seen in 229 
patients with RRMS in remission (1615.8 ng/L, SD 2662.6). When 
patients with progressive MS were included in the analysis, mean 
NfL values were similar (3080.6 ng/L, SD 4715.9 versus 1541.7 
ng/L, SD 2406.5). Heterogeneity between studies was not signifi-
cant for either analysis.
CsF nfl in progressive Ms
SPMS vers PPMS
Meta-analysis of 75 SPMS compared with 48 PPMS showed no 
difference in NfL levels (online supplementary figure 4). The 
populations appeared representative, and a funnel plot (online 
supplementary figure 5) showed no suggestion of publication bias. 
SPMS and PPMS were therefore combined for further analyses.
CSF NfL in progressive MS versus Controls
Mean NfL levels were three times higher in 158 patients with 
progressive MS (1260.4 ng/L, SD=1119.7) than 158 NINDCs 
and 14 HCs (469 ng/L, SD=306.2), and meta-analysis showed 
a significant effect size of 0.96, p<0.00001 (figure 5). Patients 
with progressive MS were older (52.6 versus 38.4 years, 
p<0.001), and sex distribution was unequal (50.4% women vs 
67.1% women, p=0.0047).
CSF NfL in RRMS versus progressive MS
Meta-analysis of five studies showed a higher CSF NfL in 176 
patients with RRMS compared with 92 patients with progressive 
MS (2124.8 ng/L vs 1121.4 ng/L) (figure 6). The effect size was 
small (0.34), but statistically significant, p=0.0108.
Demographic data were available for 87% of all subjects in this 
analysis. Patients with RRMS were younger (40.1 years vs 53.4 
years), with a greater proportion of women (74% vs 53%). 18% 
of RRMS, but only 8% of patients with progressive MS, were on 
DMT. Relapse data were available for 75% of the RRMS cohort 
(of which 40.2% were in relapse) and 83.7% of the progressive 
cohort (of which 5.2% were in relapse). There was a marked 
difference in disease duration between the cohorts—69.9 months 
for patients with RRMS compared with 167.5 months for 
patients with progressive MS. Limited subgroup data prevented 
us from being able to analyse the relationship between disease 
duration and NfL levels. Within the progressive cohort, we did 
however note that patients with SPMS had a longer mean disease 
duration than patients with PPMS (204.3 vs 59.5 months), and 
that mean CSF NfL levels between the two did not differ.
CsF nfl level in treated and untreated Ms
Meta-analysis of 163 treated and 70 untreated patients with 
MS showed no effect of treatment on CSF NfL level (online 
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Figure 3 (A) RRMS in remission versus controls (NiNDCs) and (b) RRMS in relapse versus controls (HCs and NiNDCs), subgroup and combined meta-
analysis. (a) CSF NfL levels were higher in patients with RRMS in remission than disease controls, with a moderate effect size of 0.67; (b) CSF NfL levels were 
higher in patients with RRMS in relapse than both healthy and disease controls, with a large effect size of 1.13; however, heterogeneity between studies was 
also significant. CSF, cerebrospinal fluid; HCs, healthy controls; NfL, neurofilament light chain; MS, multiple sclerosis; NiNDCs, non-inflammatory neurological 
disease controls; RRMS, relapsing remitting MS; SMD, standard mean deviation.
supplementary figure 6). The majority (78%) of patients were 
treated with low efficacy DMTs—interferon-beta, glatiramer 
acetate or teriflunomide, and 2% were treated with intravenous 
immunoglobulin. A minority were taking high efficacy DMT 
(10% natalizumab and 6% mitoxantrone). In 4% therapy was 
recorded as ‘other’.32 There was no evidence of publication bias 
(online supplementary figure 7). As expected, heterogeneity 
between study outcomes was significant.
dIsCussIOn
NfL has been proposed both as a standalone biomarker of 
neurodegeneration and as a component of a composite ‘treat-
ment target’ measure (no evidence of disease activity−5).42 The 
role of NfL levels in clinical practice (as a measure of neurode-
generation or inflammatory activity, as a tool to monitor DMT 
efficacy or as a prognostic biomarker) is yet to be determined, 
but the ability to measure blood levels increases their clinical 
utility considerably. We chose to perform a systematic review 
of NfL in CSF because, due to the proximity to the pathology, 
CSF NfL levels may more accurately reflect axonal injury than 
blood levels, and are less likely to be influenced by factors such 
as blood–brain-barrier integrity or systemic comorbidities.
CsF nfl in CdMs
CSF NfL levels were approximately three times higher in 
patients with CDMS than controls; however, heterogeneity 
between study outcomes limits our ability to suggest ‘standard’ 
or ‘expected’ CSF NfL levels.
Heterogeneity appeared to arise from NINDC populations, 
which had a mean NfL level double that of HC, but with a SD six 
times greater. This is not unexpected given that NfL is a non-spe-
cific biomarker of axonal damage. However, such a diverse 
control population is problematic when comparing results or 
combining datasets.
The two groups in this meta-analysis that referenced BioMS-EU 
guidelines on defining control populations used ‘symptomatic 
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Figure 4 (A) RRMS in relapse versus RRMS in remission and (b) all patients with MS in relapse versus all MS. (a) CSF NfL levels are higher in RRMS in 
relapse than in remission; (b) when progressive and patients with RRMS are combined as ‘all patients’, CSF NfL levels remain higher in relapse patients 
than remission patients. CSF, cerebrospinal fluid; MS, multiple sclerosis; NfL, neurofilament light chain; RRMS, relapsing remitting MS; SMD, standard mean 
deviation.
controls’ (Stilund et al29) and HCs (Trentini et al17). Seven 
papers provided details of 177 (53%) NINDCs (online supple-
mentary figure 1). Two studies included patients with idiopathic 
intracranial hypertension (IIH) (Villar et al40 and Burman et al,32 
who noted NINDCs with markedly elevated NfL levels had a 
diagnosis of IIH). IIH has been associated with high CSF NfL 
levels and is frequently included in NINDC populations.43
Six of the nine studies using NINDCs explicitly reported a 
normal CSF cell count and IgG index/OCB status. One paper 
(Lam et al38) included 2/45 NINDCs in whom OCBs were 
detected in the CSF. Two studies reported NINDCs had normal 
MRI scans,29 33 three reported MRI showed ‘no inflammation’ 
or ‘no features of MS’,32 38 44 and four did not comment.
Data were not available to characterise 155 NINDCs across 
three studies. All three studies reported normal CSF findings, 
and an absence of inflammation on MRI scans. Clinical exam-
ination was not recorded for 116 NINDCs, and was recorded as 
‘normal clinical data’ in 39. NfL levels are increased in diseases 
such as Parkinson’s disease and amyotrophic lateral Sclerosis, 
where CSF and MRI findings can be normal. CSF and MRI 
alone therefore do not exclude conditions which may result 
in elevated NfL levels. Routine use of guidelines on defining 
control populations may enable datasets to be more easily 
combined.
CsF NfL in relapse
Compared with controls, patients with RRMS had neurofila-
ment levels five times higher during remission, and nine times 
higher during relapse, replicating previous findings.25 Signif-
icant heterogeneity within the RRMS relapsing population 
warrants caution in transcribing our findings to an individual 
patient level. The source of heterogeneity here lies in the defi-
nition of ‘relapse’. Most studies defined relapse populations as 
those with a clinical relapse within the 3 months prior to CSF 
sampling. However, CSF NfL increases acutely in the context 
of relapse, peaking around 3 weeks, and remaining elevated for 
more than 15 weeks.25 45 The half-life of CSF and serum NfL is 
unknown, and none of the studies included in this meta-anal-
ysis were designed to assess the temporal relationship between 
NfL levels and relapses. Lam et al38 defined their relapse cohort 
as relapsing within 4 weeks of CSF sampling, so sampling ‘too 
early’ may explain why the lowest mean NfL (and SD) was seen 
in this study.
Only cases that were explicitly stated to be in remission were 
included in remission groups for this meta-analysis, but by groups 
excluding only those with clinical relapse (rather than radiolog-
ical evidence of activity) NfL levels may be falsely elevated in 
the ‘remission’ cohorts. Burman et al32 included patients with 
radiological findings of relapse (with or without clinical relapse) 
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Figure 5 Progressive MS (combined SPMS and PPMS) versus controls (HC and NiNDCs), subgroup and combined meta-analysis. CSF NfL levels were 
higher in patients with progressive disease than healthy and disease controls, but heterogeneity between studies was significant. HC=healthy controls; MS, 
multiple sclerosis; NiNDCs, non-inflammatory neurological disease controls; PPMS, primary progressive MS; SMD, standard mean deviation; SPMS, secondary 
progressive MS.
Figure 6 RRMS versus progressive MS (combined SPMS and PPMS) meta-analysis. CSF NfL levels were higher in RRMS than patients with progressive MS, 
with a small, but statistically significant, effect size of 0.34. PPMS, primary progressive MS; SMD, standard mean deviation; RRMS, relapsing remitting MS; 
SPMS, secondary progressive MS.
in their relapse cohort, and recorded the highest mean CSF NfL 
(and SD).
Longitudinal NfL analysis within individual patients is 
required, but has, until recently, been impractical due to the 
invasive nature of sampling. Technological advances now allow 
measurement of NfL at femtolitre concentrations using a single 
molecule array ELISA. This enables NfL levels to be measured in 
blood, and early studies suggest a good correlation between CSF 
and blood NfL levels of r=0.77 - r=0.97.41 46 Studies reviewing 
the temporal relationship between NfL levels and relapse are 
currently lacking. Future studies examining this might inform 
the rate of NfL normalisation after relapse, and if NfL levels 
peak/fall more rapidly in different disease subgroups, or in the 
context of varying degrees of clinical recovery.
To assess the effect of relapse on NfL levels in progres-
sive MS, we went on to include patients with progressive MS 
in this analysis. A statistically significant moderate effect size 
favouring those in relapse remained, suggesting a potential role 
of CSF NfL in quantification of relapsing activity across all MS 
subtypes. As DMTs become available for progressive MS, the 
ability to identify markers of active inflammatory disease may 
play an important role in decisions regarding treatment options 
and in monitoring.
CsF nfl in progressive Ms
CSF NfL levels in patients with progressive MS were twice that of 
controls (although confounders were evident), but significantly 
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lower than in patients with RRMS (relapse and remission). 
Heterogeneity reflects the expected differences in demographics 
and disease activity between the cohorts, and although the RRMS 
studies with the highest proportion of patients in relapse did not 
have the highest mean NfL, the effect of relapses is reflected 
by the lower SD in the progressive cohort compared with the 
RRMS cohort.
To assess whether CSF NfL was significantly different between 
RRMS in remission and progressive disease, we compared data 
from 229 patients with RRMS in remission with 158 patients 
with progressive MS. Patients with RRMS in remission had a 
higher mean NfL level (1615.8 ng/L, SD=2662.6 vs 1260.4 ng/L, 
SD=1119.7), but was not statistically significant (p=0.072). 
The trend in these data is consistent with the hypothesis that 
intermittent, inflammatory, disease activity might have a more 
pronounced effect on CSF NfL level than cumulative neuroaxonal 
loss. However, a purely clinical definition of remission may have 
missed subclinical relapses, resulting in a falsely high CSF NfL in 
the remission cohort.
CsF nfl and dMT
High efficacy DMTs (such as Natalizumab and Fingolimod) are 
associated with reductions in NfL level post-treatment, irre-
spective of clinical course, and independent of relapse rate, 
to the point that levels are not significantly higher than in 
HCs.30 31 41 47 49 Our meta-analysis however showed no effect of 
DMT on CSF NfL levels. This may be because the our numbers 
in this analysis were small, and the majority of our cohorts were 
treated with less efficacious agents, which are known to reduce 
relapses to a lesser degree.
Limitations of our meta-analysis include the fact that a single 
author reviewed the literature, and that studies were excluded 
due to insufficient data. We contacted the authors, but had to 
exclude six papers, and in two papers had to estimate the mean 
and SD using the median and range. A further limitation was 
that we used raw data (uncorrected for age). The reason for 
this was that only some studies corrected data for age (when 
analysing results), and in others the demographic data provided 
were not sufficiently detailed to allow correction for age within 
subgroups. Studies that analysed correlation between NfL level 
and age showed mixed results. Four studies found no correlation 
(17 34 40 48). Two found a positive correlation in control popula-
tions.32 33 Four papers reported a positive correlation in patients 
with MS, but only one was statistically significant (r=0.216, 
p<0.0008).40 Others reported ‘age dependency’ and adjusted 
their analyses.27 44 Overall, literature suggests a positive correla-
tion between age and CSF NfL level. However, the small effect 
of age on NfL levels is probably masked by higher disease-associ-
ated influences on NfL levels in the young MS population.
This meta-analysis provides evidence that CSF neurofilament 
levels are significantly higher in pwMS than controls, and in 
pwMS in relapse compared with remission, regardless of MS 
subtype. Raised CSF NfL levels in all pwMS suggest that axonal 
damage occurs throughout the disease course, and not simply 
in the context of relapses, or as a late phenomenon. CSF NfL 
levels do not clearly distinguish MS subtypes, and NfL is not 
a useful tool for ‘staging’ MS. In all patients, relapse appears 
to be a stronger driver of NfL levels than progressive disease. 
This suggests that CSF NfL correlates more closely with acute 
inflammation than chronic neurodegeneration, and that NfL 
may have greater clinical utility as a biomarker of disease activity 
than disease progression.
There is now unequivocal data supporting a high correlation 
between CSF and blood NfL levels. In this new era of ultra-high 
sensitivity biomarkers, we are moving from CSF to serum-based 
assays, which offer advantages such as longitudinal analysis. This 
is therefore an appropriate time to systematically evaluate the 
literature on CSF NfL in order to direct future studies.
In summary, we have shown that CSF NfL levels are higher in 
all subtypes of MS compared with healthy and disease controls. 
Furthermore we have shown that CSF NfL levels correlate most 
closely with inflammatory disease activity.
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